NIAID principal deputy director Dr. Hugh Auchincloss addresses the audience at the opening
of the first study of the Sino-U.S. (Henan) Tuberculosis Prevention and Treatment Research Institute. Dr. Karyl Barron, deputy director of NIAID’s Division of Intramural Research, looks on.
NIAID and its partner, the Henan Provincial Health Bureau, recently launched the first study of the Sino-U.S. (Henan) Tuberculosis Prevention
and Treatment Research Institute at the Henan Provincial Chest Hospital in Zhengzhou, China. The institute aims to develop new and improved ways to diagnose, treat and prevent multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (TB). The research will be conducted by investigators from NIAID, the Henan Provincial Chest Hospital and Fudan University in Shanghai. The institute’s first patient was enrolled into a natural history study the same day.
The emergence of drug-resistant TB is a major health issue globally and an increasing concern in China. The World Health Organization estimates
that almost half of all reported cases of MDR TB in 2008 occurred in China and India, with both countries reporting approximately 100,000 new cases each.
An NIAID delegation joined U.S. Ambassador to China Jon Huntsman and HHS Health Attaché Elizabeth Yuan; representatives from the U.S. Centers for Disease Control and Prevention, Henan Provincial Health Bureau and Henan Provincial Chest Hospital; and members of the public to commemorate the opening.